Previous Close | 2.6700 |
Open | 2.4390 |
Bid | 0.0000 x 4000 |
Ask | 0.0000 x 1800 |
Day's Range | 2.7500 - 3.0400 |
52 Week Range | 0.1600 - 5.4900 |
Volume | |
Avg. Volume | 4,383 |
Market Cap | 3.659M |
Beta (5Y Monthly) | 1.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -12.5900 |
Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
HOUSTON, April 24, 2024--Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
HOUSTON, April 02, 2024--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
HOUSTON, March 19, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).